You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: October 31, 2024

CLINICAL TRIALS PROFILE FOR YERVOY


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for YERVOY

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00170157 ↗ Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed Medarex Phase 2 2004-06-01 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗ Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed National Cancer Institute (NCI) Phase 2 2004-06-01 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗ Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed U.S. Army Medical Research Acquisition Activity Phase 2 2004-06-01 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
NCT00170157 ↗ Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed United States Department of Defense Phase 2 2004-06-01 RATIONALE: Androgens can cause the growth of prostate cancer cells. Antihormone therapy, such as leuprolide acetate, goserelin, flutamide, or bicalutamide may lessen the amount of androgens made by the body. Monoclonal antibodies, such as ipilimumab, can block cancer growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry cancer-killing substances to them. Giving antihormone therapy together with ipilimumab may kill more tumor cells. PURPOSE: This randomized phase II trial is study how well giving hormone therapy and ipilimumab together works in treating patients with advanced prostate cancer.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for YERVOY

Condition Name

Condition Name for YERVOY
Intervention Trials
Melanoma 42
Metastatic Melanoma 26
Renal Cell Carcinoma 14
Non-Small Cell Lung Cancer 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for YERVOY
Intervention Trials
Melanoma 88
Carcinoma 54
Carcinoma, Renal Cell 33
Lung Neoplasms 31
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for YERVOY

Trials by Country

Trials by Country for YERVOY
Location Trials
Japan 189
China 125
Australia 123
Canada 92
Spain 76
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for YERVOY
Location Trials
Texas 106
California 93
Massachusetts 75
Pennsylvania 75
New York 71
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for YERVOY

Clinical Trial Phase

Clinical Trial Phase for YERVOY
Clinical Trial Phase Trials
Phase 4 3
Phase 3 20
Phase 2/Phase 3 7
[disabled in preview] 117
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for YERVOY
Clinical Trial Phase Trials
Recruiting 107
Active, not recruiting 69
Completed 44
[disabled in preview] 31
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for YERVOY

Sponsor Name

Sponsor Name for YERVOY
Sponsor Trials
Bristol-Myers Squibb 133
National Cancer Institute (NCI) 53
M.D. Anderson Cancer Center 35
[disabled in preview] 14
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for YERVOY
Sponsor Trials
Other 265
Industry 237
NIH 55
[disabled in preview] 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.